Lurbinectedin is a medication used for the treatment of advanced solid tumors, including small cell lung cancer. However, there is limited information available regarding the potential risks of lurbinectedin in breast milk.

According to the drug label [2], it is not known whether lurbinectedin is excreted in human milk. Additionally, there are no data on the effects of lurbinectedin on breastfed infants or on milk production. Therefore, women who are taking lurbinectedin should not breastfeed during treatment and for at least 2 weeks after the last dose.

While there is no information on the potential risks of lurbinectedin in breast milk, it is known that the drug can cause serious side effects in patients. These side effects include myelosuppression, hepatotoxicity, and embryo-fetal toxicity [2].

In conclusion, the potential risks of lurbinectedin in breast milk are currently unknown. Therefore, women who are taking lurbinectedin should not breastfeed during treatment and for at least 2 weeks after the last dose. It is important for patients to discuss any concerns about medication use during breastfeeding with their healthcare provider.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
[3] https://pp.jazzpharma.com/pi/zepzelca.ca.PM-en.pdf